Euloge Kpamegan

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Oliver Sartor, Johann S. de Bono, Kim N. et al. · New England Journal of Medicine · 2021 · 2.6K citations · Full text

Medicine, Oncology, Radiation Oncology +17

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

Michael J. Morris, Daniel Castellano, Ken Herrmann et al. · The Lancet · 2024 · 258 citations · Full text

Medicine, Oncology, Urology +17

Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma

Dorothy A. White, Philippe Camus, Masahiro Endo et al. · American Journal of Respiratory and Critical Care Medicine · 2010 · 211 citations

Medicine, Oncology, Pharmacotherapy +14

Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).

Michael J. Morris, Johann S. de Bono, Kim N. et al. · Journal of Clinical Oncology · 2021 · 74 citations

Medicine, Oncology, Pharmacology +17

LBA13 Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)

Oliver Sartor, D.E. Castellano Gauna, Ken Herrmann et al. · Annals of Oncology · 2023 · 68 citations · Full text

Medicine, Oncology, Urology +16